Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laurus LabsBOM:540222 +6.99%66 Days Inventory is 282.70 as of Jun. 2026, which is 32% above its 10-year median of 213.68. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹816.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Laurus Labs ranks worse than 79.83% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Laurus Labs's Average Total Inventories for the
three
months ended in Jun. 2026 was ₹23,422 Mil. Laurus Labs's Cost of Goods Sold for the
three
months ended in Jun. 2026 was ₹7,560 Mil.
Hence, Laurus Labs's Days Inventory for the
three
months ended in Jun. 2026 was 282.70.
The historical rank and industry rank for Laurus Labs's Days Inventory or its related term are showing as below:
BOM:540222'
s Days Inventory Range Over the Past 10 Years
Min: 177.99 Med: 213.68 Max: 282.55
Current: 272.36
During the past 13 years, Laurus Labs's highest Days Inventory was 282.55. The lowest was 177.99. And the median was 213.68.
BOM:540222's Days Inventory is ranked worse than 79.83% of 922
companies
in the Drug Manufacturers industry
Industry Median: 164.58
vs BOM:540222: 272.36
Laurus Labs's Days Inventory
increased
from Jun. 2025 (277.26) to Jun. 2026 (282.70).
It might indicate that Laurus Labs's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Laurus Labs's Inventory Turnover for the
three
months ended in Jun. 2026 was 0.32.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Laurus Labs's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 1.16.
Laurus Labs (BOM:540222) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Laurus Labs's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Laurus Labs's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Laurus Labs Days Inventory Related Terms
Laurus Labs Days Inventory Historical Data
* Premium members only.
The historical data trend for Laurus Labs's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Days Inventory distribution charts can be found below:
* The bar in red indicates where Laurus Labs's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laurus Labs (BOM:540222) has a Days Inventory of 282.70 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Laurus Labs and its competitors. This is 32% above median its historical median of 213.68. Over the past decade, Laurus Labs' Days Inventory has ranged from 177.99 to 282.55. According to the industry distribution chart, Laurus Labs ranks #736 out of 922 companies in the Drug Manufacturers industry, placing it in the top 79.8%.
Is Laurus Labs' Days Inventory too high?
Laurus Labs' current Days Inventory of 282.70 is 32% above median its 10-year median of 213.68. Over the past 10 years, this metric has ranged from a low of 177.99 to a high of 282.55. The Drug Manufacturers industry median Days Inventory is 164.58. Laurus Labs' value of 282.70 is 71.8% above this industry median. Based on the distribution chart, Laurus Labs ranks #736 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #736 out of 922 companies for Days Inventory. This places Laurus Labs in the lower half of its industry. The industry median Days Inventory is 164.58. Laurus Labs' value of 282.70 is 71.8% above this benchmark. Historically, Laurus Labs' own Days Inventory has ranged from 177.99 to 282.55 over the past decade. While the company's 10-year median is 213.68 vs. the industry median of 164.58, Laurus Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.58, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laurus Labs's current Days Inventory of 282.70 is 71.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Laurus Labs and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current Days Inventory is 282.70, which is 32% above median its own 10-year median of 213.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹816.30, compared to a current price of ₹1,714.25 — trading 110% above its estimated fair value. The current Days Inventory is 282.70, which is 32% above median its 10-year median of 213.68 and 71.8% above the Drug Manufacturers industry median of 164.58. Laurus Labs' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Days Inventory is 282.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,714.25 is trading 110% above its estimated GF Value™ of ₹816.30.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
Days Inventory: 282.70 (32% above median its 10-year median of 213.68)
GF Value™: ₹816.30 vs. price of ₹1,714.25 (110% above fair value)
Industry Position: 71.8% above the Drug Manufacturers median (#736 of 922)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score
Get the complete analysis for BOM:540222
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
